Cargando…

Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer

BACKGROUND: Observational studies in metastatic breast cancer (MBC) show that long-term overall survival (OS) is associated with limited tumor burden, or oligo-MBC (OMBC). However, a uniform definition of OMBC is lacking. In this real-world nationwide cohort, we aimed to define the optimal OMBC thre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steenbruggen, Tessa G, Schaapveld, Michael, Horlings, Hugo M, Sanders, Joyce, Hogewoning, Sander J, Lips, Esther H, Vrancken Peeters, Marie-Jeanne T, Kok, Niels F, Wiersma, Terry, Esserman, Laura, van ‘t Veer, Laura J, Linn, Sabine C, Siesling, Sabine, Sonke, Gabe S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099998/ https://www.ncbi.nlm.nih.gov/pubmed/33977227 http://dx.doi.org/10.1093/jncics/pkab010

Ejemplares similares

Survival and prognostic factors in oligometastatic breast cancer
por: van Ommen-Nijhof, Annemiek, et al.
Publicado: (2022)

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?
por: Steenbruggen, Tessa G, et al.
Publicado: (2015)

3447 Effects of intranasal ketamine on uncontrolled cancer related pain
por: Singh, Vinita, et al.
Publicado: (2019)

Immune landscape of breast tumors with low and intermediate estrogen receptor expression
por: Voorwerk, Leonie, et al.
Publicado: (2023)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival
por: van der Voort, Anna, et al.
Publicado: (2022)

Teacher Stress Inventory: validation of the Greek version and perceived stress levels among 3,447 educators
por: Kourmousi, Ntina, et al.
Publicado: (2015)

Survival after Locoregional Recurrence or Second Primary Breast Cancer: Impact of the Disease-Free Interval
por: Witteveen, Annemieke, et al.
Publicado: (2015)

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer
por: Steenbruggen, Tessa G., et al.
Publicado: (2023)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
por: Dackus, Gwen M. H. E., et al.
Publicado: (2020)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Changes in survival in de novo metastatic cancer in an era of new medicines
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Breast-Contour-Preserving Procedure as a Multidisciplinary Parameter of Esthetic Outcome in Breast Cancer Treatment in The Netherlands
por: van Bommel, Annnelotte, et al.
Publicado: (2019)

Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients
por: Witteveen, Annemieke, et al.
Publicado: (2015)

Socioeconomic status and its relation with breast cancer recurrence and survival in young women in the Netherlands
por: van Maaren, Marissa C., et al.
Publicado: (2022)

Associations of hospital volume and hospital competition with short-term, middle-term and long-term patient outcomes after breast cancer surgery: a retrospective population-based study
por: van der Schors, Wouter, et al.
Publicado: (2022)

Imaging of Oligometastatic Disease
por: Vietti Violi, Naik, et al.
Publicado: (2022)

Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer
por: Reverberi, C., et al.
Publicado: (2020)

Investigation of the Definition of De Novo Oligometastatic Nasopharyngeal Carcinoma: A Retrospective Study
por: Wang, Hongmei, et al.
Publicado: (2021)

Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease
por: Parikh, Neil R., et al.
Publicado: (2019)

Myocardial dysfunction in long‐term breast cancer survivors treated at ages 40–50 years
por: Jacobse, Judy N., et al.
Publicado: (2019)

Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
por: Preisser, Felix, et al.
Publicado: (2021)

Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation
por: de Jong, Vincent M. T., et al.
Publicado: (2022)

Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple‐negative breast cancer
por: Heeg, Erik, et al.
Publicado: (2019)

Oligometastatic Prostate Cancer
por: Stevens, Daniel J., et al.
Publicado: (2016)

Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study
por: van Loevezijn, Ariane A., et al.
Publicado: (2020)

Health-Related Quality of Life following Cytoreductive Radical Prostatectomy in Patients with De-Novo Oligometastatic Prostate Cancer
por: Chaloupka, Michael, et al.
Publicado: (2021)

Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer
por: Imber, Brandon S., et al.
Publicado: (2020)

Stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma and oligometastatic liver disease
por: Gerum, Sabine, et al.
Publicado: (2018)

Additional value of (18)F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer
por: van Ramshorst, Mette S., et al.
Publicado: (2017)

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial
por: Schouten, Philip C., et al.
Publicado: (2016)

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
por: Rigter, L S, et al.
Publicado: (2013)

Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion
por: Leblanc, Dominique, et al.
Publicado: (2023)

The biology and treatment of oligometastatic cancer
por: Reyes, Diane K., et al.
Publicado: (2015)

Radiotherapy for Oligometastatic Lung Cancer
por: Bergsma, Derek P., et al.
Publicado: (2017)

Highlights on the Management of Oligometastatic Disease
por: Alshehri, Salem M., et al.
Publicado: (2020)

Evaluating the Age‐Based Recommendations for Long‐Term Follow‐Up in Breast Cancer
por: Witteveen, Annemieke, et al.
Publicado: (2020)

Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?
por: Peeters, Stephanie T. H., et al.
Publicado: (2021)

Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients
por: Morales-Orue, Ignacio, et al.
Publicado: (2020)

Surgical treatment in oligometastatic breast cancer
por: Vargas, Catalina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g5rmib0vk5ebefclhmf539s6n6